BMS acquires MyoKardia, maker of drugs for cardiovascular disease, for $13.1B
The companies expect the deal to close in the fourth quarter. MyoKardia’s lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.